Voyager Therapeutics Inc VT6
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if VT6 is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $7.97
- Day Range
- $8.02–8.02
- 52-Week Range
- —–—
- Bid/Ask
- $0.00 / $0.00
- Market Cap
- $436.24 Mil
- Volume/Avg
- 0 / —
Key Statistics
- Price/Earnings (Normalized)
- 2.81
- Price/Sales
- 3.53
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 162
Comparables
Valuation
|
Metric
|
VT6
|
MORF
|
DICE
|
|---|---|---|---|
Price/Earnings (Normalized) | 2.81 | — | — |
Price/Book Value | 1.38 | 2.00 | 4.38 |
Price/Sales | 3.53 | — | — |
Price/Cash Flow | 50.42 | — | — |
Price/Earnings
VT6
MORF
DICE
Financial Strength
|
Metric
|
VT6
|
MORF
|
DICE
|
|---|---|---|---|
Quick Ratio | 5.55 | 37.20 | 25.69 |
Current Ratio | 5.64 | 38.17 | 25.88 |
Interest Coverage | — | — | −214.24 |
Quick Ratio
VT6
MORF
DICE
Profitability
|
Metric
|
VT6
|
MORF
|
DICE
|
|---|---|---|---|
Return on Assets (Normalized) | 1.90% | −18.85% | −18.86% |
Return on Equity (Normalized) | 2.87% | −19.43% | −20.04% |
Return on Invested Capital (Normalized) | −1.88% | −23.26% | −22.67% |
Return on Assets
VT6
MORF
DICE
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Ybkmlpb | Tvlqjj | $124.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Gbhlvvgp | Qfxjlvr | $114.2 Bil | |||
| Moderna Inc
MRNA
| Fkzxlqbt | Vhcl | $53.7 Bil | |||
| argenx SE ADR
ARGX
| Bgxrfls | Jrpg | $23.0 Bil | |||
| BioNTech SE ADR
BNTX
| Wrhxbqpz | Vfcwh | $22.2 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Jhyyzhzx | Xbvpth | $20.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Chwgktqd | Xyjvkt | $15.9 Bil | |||
| United Therapeutics Corp
UTHR
| Bzwkhgyg | Bcb | $12.8 Bil | |||
| Incyte Corp
INCY
| Ykbwlnbfk | Nmczp | $12.2 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Cplfhsnnnm | Zzgwkh | $12.2 Bil |